<img height="1" width="1" style="display:none" src="https://q.quora.com/_/ad/fddcdc9dc8954bf7bdefaa9d33414665/pixel?tag=ViewContent&amp;noscript=1">

The ResoluteAI Difference: Searching at the Speed of Innovation

September 06, 2019

Digital transformation and advanced technologies have accelerated the speed of clinical trials and the processes associated with creating, approving, and marketing new life-changing drugs. A recent Drugbank post titled Cannabinoids in Epilepsy: A New Era of Treatment reveals that the FDA is moving toward approving Epidiolex, a cannabis-derived product for the treatment of two forms of treatment-resistant childhood epilepsies: Lennox-Gastaut Syndrome and Dravet Syndrome. Epidiolex consists of purified cannabidiol (CBD), a key medicinal component of the marijuana plant. 

This developing news profoundly impacts the spectrum of stakeholders who have a financial, medical, or other vested interest in the FDA’s findings. However, accessing and contextualizing these disparate sources of information on a continually evolving subject matter can feel overwhelming, if not impossible. However, a quick search on Resolute.ai indicates that there are currently 5 ongoing clinical trials testing the efficacy of CBD in treating epilepsy. There are also 49 grants in progress, 29 of which are sponsored by the National Institute on Drug Abuse. The patent leader in this space is GW Research in Cambridge, UK. 

Drugbank reports:

Cannabidivarin (CBDV) is being actively developed by GW Pharmaceuticals as the experimental compound GWP42006 as it has "shown the ability to treat seizures in pre-clinical models of epilepsy with significantly fewer side effects than currently approved anti-epileptic drugs". Unfortunately, as of February 2018, GW Pharmaceuticals announced that their Phase 2a placebo-controlled study of CBDV for focal seizure did not reach its primary endpoints. However, they will continue to study its use in epilepsy and are expanding their investigations to include its potential use in Autism Spectrum Disorder, Rett syndrome and Fragile X among others.

Solution Sheet

How AI Search Improves Enterprise R&D

Download the solution sheet to learn how artificial intelligence is connecting businesses to data through advanced technologies.

Download the Solution Sheet

ResoluteAI is able to provide researchers, scientists, and pharmaceutical professionals with detailed information and data -- even from disparate and siloed locations, organizations, and institutions -- on groundbreaking clinical trials being conducted across the world. To see how ResoluteAI can deliver the full research picture, go to Scientific Research Platform and request a demo. 




ResoluteAI is the research platform for science. Foundation lets commercial science enterprises search aggregated scientific, regulatory, and business databases simultaneously. Nebula is our enterprise search tool for science. Combined with our interactive analytics and downloadable visualizations, ResoluteAI helps make connections that lead to breakthrough discoveries. Used in R&D, medical affairs, post market surveillance, and pharmacovigilance by scientific organizations around the world, ResoluteAI won the BCS Search Industry Award for Most Promising Start-Up in 2021.